Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/108906| Title: | Biomarkers predicting sensitivity to PP2A activation therapy in cancer |
| Authors: | Grech, Godfrey Scerri, Christian Saliba, Christian Baldacchino, Shawn |
| Keywords: | Breast -- Cancer -- Classification Breast -- Cancer -- Treatment Phosphoprotein phosphatases -- Inhibitors Protein phosphatase 2 Biochemical markers -- Diagnostic use |
| Issue Date: | 2018 |
| Publisher: | Patent Cooperation Treaty (PCT) |
| Citation: | Grech, A, Scerri, C., Saliba, C., & Baldacchino, S. (2018). Biomarkers predicting sensitivity to PP2A activation therapy in cancer. International application published under the Patent Cooperation Treaty (PCT-EP2018-057189). International Publication WO 2018/172419 Al. |
| Abstract: | The invention relates to the treatment and classification of cancer, in particular breast cancer. It relates to identifying patients who are likely to respond to cancer therapy with a PP2 A activator. Background: The provision of new treatments for cancer is of high importance, including for cancers resistant to known treatments. There is also a need for identification of markers that allow for detection, prognosis and classification of cancer, and which can predict responsiveness of a patient to a given therapy. The deregulation of the protein phosphatase 2A (PP2A) complex is known to be a common event in cancer [Grech et al; Tumor Biol; DOl 10.1007/s13277-016-5145-4 (2016)]. |
| URI: | https://patents.google.com/patent/WO2018172419A1/en?oq=PCT-EP2018-057189 https://www.um.edu.mt/library/oar/handle/123456789/108906 |
| Appears in Collections: | Scholarly Works - FacM&SPat |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Patent_WO2018172419A1.pdf | 901.76 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.